Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-5.31 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-5.31 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the current market conditions. They did not provide specific guidance or revenue expectations.
Management did not provide specific revenue figures or guidance for future quarters.
The company acknowledged ongoing challenges in the market.
Mirum Pharmaceutical's earnings report showed a significant loss per share, which contributed to a 4.38% drop in stock price. The lack of revenue figures and guidance suggests uncertainty about the company's financial outlook. Investors may be concerned about the ongoing challenges mentioned by management, which could impact future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BANK MONTREAL QUE
Aug 27, 2019